[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370798-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370798-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","detecting-likely-germline-variants-during-tumor-based-molecular-profiling-review","Detecting likely germline variants during tumor-based molecular profiling - Review","","Molecular profiling of tumors increasingly guides cancer diagnosis, prognosis, and treatment planning, while also revealing germline DNA alterations despite its original focus on somatic variants. This review explains why careful clinical interpretation is required when germline risk testing is identified incidentally during NGS-based tumor profiling. It contrasts comprehensive germline testing with tumor-based platforms across platforms, sample types, and analytical methods, highlighting implications for precision oncology and germline cancer risk surveillance and management.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/detecting-likely-germline-variants-during-tumor-based-molecular-profiling-review/370798/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/detecting-likely-germline-variants-during-tumor-based-molecular-profiling-review/370798.png","ImageObject",300,407,{"name":42,"@type":43},"supergirl","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why can tumor-based NGS profiling detect germline variants?","Question",{"text":63,"@type":64},"Tumor-based panels primarily target somatic alterations, but they can also identify germline DNA changes because cells throughout the body contain inherited DNA. This means variants may reflect germline origin and require clinical interpretation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the key limitation of tumor-based profiling for germline identification?",{"text":68,"@type":64},"Tumor-based profiling alone cannot reliably distinguish somatic versus germline origin without additional confirmatory germline analysis. Further testing is needed to clarify variant provenance.",{"name":70,"@type":61,"acceptedAnswer":71},"How do defects in germline DNA repair pathways contribute to tumorigenesis?",{"text":72,"@type":64},"Deleterious germline variants can disrupt cancer susceptibility genes involved in DNA repair, cell cycle regulation, and telomere biology. For example, HRR defects can impair accurate double-strand break repair and increase genomic instability, while mismatch repair pathway disruptions can promote microsatellite instability.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370798,1791529569,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","The Journal of Clinical Investigation REVIEW  \nDetecting likely germline variants during tumor-based molecular profiling  \nDiana Jaber,1 Jessica Zhang,1 and Lucy A. Godley1,2  \n1Department of Medicine, Northwestern Medicine, Chicago, Illinois, USA. 2Division of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.  \nAs the use of molecular profiling of tumors expands, cancer diagnosis, prognosis, and treatment planning increasingly rely on the information it provides. Although primarily designed to detect somatic variants, next-generation sequencing (NGS) tumor-based profiling also identifies germline DNA alterations, necessitating careful clinical interpretation of the data. Traditionally, germline risk testing has depended on prioritizing individuals based on physical exam findings consistent with known hereditary cancer syndromes, tumor-specific features, age at diagnosis, personal history, and family history. As NGS-based molecular profiling is used increasingly to diagnose, prognosticate, and follow cancer progression, DNA variants that are likely to be of germline origin are identified with increased frequency. Because pathogenic/likely pathogenic germline variants are critical biomarkers for risk stratification and treatment planning, consensus guidelines are expanding to recommend comprehensive germline testing for more cancer patients. This Review highlights the nuances of identifying DNA variants of potential germline origin incidentally at the time of NGS-based molecular profiling and emphasizes key differences between comprehensive germline versus tumor-based platforms, sample types, and analytical methodologies. In the growing era of precision oncology, clinicians should beadept at navigating these distinctions to optimize testing strategies and leverage insights regarding germline cancer risk surveillance and management for all people with cancer.  \nIntroduction  \nTumor-based profiling, typically performed using panels based on next-generation sequencing (NGS), is utilized widely to identify driver DNA alterations that inform diagnosis, prognosis, and targeted intervention. Although it is primarily designed to characterize the tumor somatic landscape, this approach also identifies germline variants, since all non-germ cells in the body contain inherited DNA. Germline cancer predisposition often drives tumorigenesis (1–3), underscoring the importance of germline variant detection during tumor-based profiling. Deleterious germline variants have been implicated in many cancer susceptibility genes (CSGs), several of which give rise to clinical phenotypes that inform the use of targeted therapies (4–7) . As germline variants gain recognition as predictive biomarkers of therapeutic response, clinical guidelines for both solid and hematopoietic malignancies (HMs) now advocate for more comprehensive germline testing (8–21) . However, tumor-based profiling alone cannot reliably distinguish between somatic and germline origin of variants without further confirmatory germline analysis. As the number of genes linked to germline cancer predisposition expands, oncology providers must be equipped to identify variants from tumor-based profiling that are of potential germline origin.  \nConflict of interest: The authors have declared that no conflict of interest exists. Copyright: © 2025, Jaber et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.  \nReference information: J Clin Invest. 2025;135(15):e190264 .  \n[https://doi.org/10.1172/JCI190264](https://doi.org/10.1172/JCI190264) .  \nThe role of germline pathogenicityin tumorigenesis  \nDeleterious germline variants disrupt the function of CSGs that encode components integral to DNA repair, cell cycle regulation, telomere biology, and other essential cellular processes. Defects in homologous recombination repair (HRR) genes, ","cbCaioGyOPN2fE4u","https://ap.wps.com/l/cbCaioGyOPN2fE4u","pdf",1298469,14,"English","# Introduction\n# The role of germline pathogenicity in tumorigenesis\n## Homologous recombination repair (HRR) defects\n## Mismatch repair (MMR) pathway disruptions","[{\"question\":\"Why can tumor-based NGS profiling detect germline variants?\",\"answer\":\"Tumor-based panels primarily target somatic alterations, but they can also identify germline DNA changes because cells throughout the body contain inherited DNA. This means variants may reflect germline origin and require clinical interpretation.\"},{\"question\":\"What is the key limitation of tumor-based profiling for germline identification?\",\"answer\":\"Tumor-based profiling alone cannot reliably distinguish somatic versus germline origin without additional confirmatory germline analysis. Further testing is needed to clarify variant provenance.\"},{\"question\":\"How do defects in germline DNA repair pathways contribute to tumorigenesis?\",\"answer\":\"Deleterious germline variants can disrupt cancer susceptibility genes involved in DNA repair, cell cycle regulation, and telomere biology. For example, HRR defects can impair accurate double-strand break repair and increase genomic instability, while mismatch repair pathway disruptions can promote microsatellite instability.\"}]","Detecting likely germline variants during tumor-based molecular profiling - Review | PDF",1790190375,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/511a3447105305ad58cc8f85fb20b5a2.webp",983,1315,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c788ec1820e202f7e634780c780011c8.webp",982,1314,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c3dbb161aa51cc3133ffd287d7a3597.webp",981,1312,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62acceef6c23b924a9c50708e502b3aa.webp",980,1311]